Transcription factors Elk-1 and SRF are engaged in IL1-dependent regulation of ZC3H12A expression
© Kasza et al; licensee BioMed Central Ltd. 2010
Received: 10 August 2009
Accepted: 6 February 2010
Published: 6 February 2010
MCPIP is a novel CCCH zinc finger protein described as an RNase engaged in the regulation of immune responses. The regulation of expression of the gene coding for MCPIP - ZC3H12A is poorly explored.
Here we report that the proinflammatory cytokine IL-1β rapidly induces the synthesis of MCPIP in primary monocyte-derived macrophages and HepG2 cells. This up-regulation takes place through the MAP kinase pathway and following activation of the transcription factor Elk-1. Using a ZC3H12A reporter construct we have shown that a ZC3H12A promoter region, stretching from -76 to +60, mediates activation by IL-1β. This region contains binding sites for Elk-1 and its partner SRF. Chromatin immunoprecipitation analysis confirms in vivo binding of both transcription factors to this region of the ZC3H12A promoter.
We conclude that the transcription factor Elk-1 plays an important role in the activation of ZC3H12A expression in response to IL-1β stimulation.
MCPIP has RNase activity that prevents some immune disorders by direct control of the stability of a set of inflammatory transcripts [1, 2]. MCPIP-deficient mice die within 12 weeks with the symptoms of severe inflammatory changes. Among transcripts destabilized by MCPIP are the mRNAs for IL-6, IL-12p40, calcitonin receptorand and IL-1β [1, 2]. MCPIP contains a PIN domain, responsible for it's enzymatic activity and CCCH zinc finger domain, partially also engaged in the control of transcripts decay [1, 2]. MCPIP is induced in human peripherial blood monocytes by monocyte chemoattractant protein (MCP-1) and this phenomenon resulted in the name of this protein as a MCP-1 inducible protein (MCPIP) . The significance of MCPIP in the course of inflammation is manifested also in the development of cardiovascular diseases. Elevated level of MCPIP is associated with ischemic heart disease . Recently it was found that Toll-like receptors are involved in the activation of mice Zc3h12a (gene encoding MCPIP). The activation of Zc3h12a was revealed by microarray analysis of RNA from macrophages of wild-type, Myd88-/- and Trif-/-mice stimulated with liposacharide (LPS) . We have observed that the level of transcript for MCPIP is rapidly induced by IL-1β in monocytes, fibroblasts and hepatoma HepG2 cells . IL-1β is a proinflammatory cytokine produced very early in response to multiple stress. It exerts pleiotropic effects on different cell types. Binding of IL-1β to IL-1RI leads to activation of the kinase TAK1, which finally results in the activation of NFκB but also activation of MAP kinases (namely ERK, p38 and JNK) .
Among different transcription factors phosphorylated by MAPKs are the ternary complex factors (TCF), the subfamily of ETS-domain transcription factors . The TCF subfamily include Elk-1, SAP-1 and SAP2/ERP/Net. These proteins form ternary complexes on target promoters together with MADS-box protein, serum response factor (SRF). All TCFs share the ETS-domain which is engaged in DNA-binding, the B-box responsible for association with SRF, the transcriptional-activation domain that can be phosphorylated on multiple serine and threonine residues, and the docking domain which interacts with MAPKs . Elk-1 and SAP-1 are thought to act as activators whereas SAP-2 is thought to play mainly a repressive role. A series of events initiated by phosphorylation of transcription factors from the TCF subfamily are still under investigation. Phosphorylation induces conformational changes and influences the interaction of transcription factors with other co-activators/co-repressors. The details of this process are quite well understood for Elk-1. Phosphorylation leads to its de-repression through the reversing of its sumoylation and subsequent dissociation of HDAC-2 . Phosphorylated Elk-1 recruits Mediator through the coactivator Sur-2/Med23 and interacts with p300/CBP which causes the enhancement of acetylation of histones of target promoters [7, 8]. Recently it was also shown that histone acetylation initiated by phoshorylation of Elk-1 on the c-fos promoter leads to association of a second transcription factor, NFI, which in turn leads to the recruitment of the basal machinery and subsequent promoter activation .
The mechanisms controlling the regulation of MCPIP expression are largely unknown. Here, we have shown that IL-1β regulates expression of the gene coding for MCPIP - ZC3H12A through the activation of the ERK pathway. We have found that Elk-1 and SRF are transcription factors engaged in this regulation.
IL-1β regulates the expression of ZC3H12A via activation of the NFkB and ERK pathways
Since MCPIP plays a crucial role in the regulation of inflammation we decided to confirm the involvement of ERK pathway in the regulation of IL-1β stimulated ZC3H12A expression in human monocyte-derived macrophages. In macrophages treated with IL-1β the level of MCPIP mRNA was elevated and this effect was partially blocked by ERK inhibitor - U0126 (Fig. 1C). These data show that the observed mechanism of ERK-dependent regulation of ZC3H12A by IL-1β is not restricted to HepG2 cells.
The ZC3H12A promoter is regulated by the transcription factor Elk-1
To demonstrate that endogenous Elk-1 and SRF can bind to the ZC3H12A promoter in vivo we carried out a chromatin immunoprecipitation experiment in HepG2 cells. In the presence of Elk-1 antibodies, the ZC3H12A promoter was precipitated from formaldehyde cross-linked total cell lysates (Fig. 3B, top panel, lane 2), whereas control antibodies precipitated background levels of the ZC3H12A promoter (Fig. 3B and 3C, top panels, lanes 1 and 3). The promoter of ZC3H12A was also precipitated in the presence of SRF antibodies (Fig. 3C, top panel, lane 2). IL-1β stimulation had no effect on the association of either Elk-1 or SRF with the ZC3H12A promoter (Fig. 3B and 3C, top panel, lane 4). Both Elk-1 and SRF were also detected as constitutively associated with the promoter of the well characterized target gene, an EGR-1 (Fig. 3B and 3C, bottom panels lanes 2 and 4). These observations demonstrate that endogenous Elk-1 and SRF bind to the ZC3H12A promoter in vivo, thereby demonstrating that the regulatory effects of Elk-1 and SRF on ZC3H12A expression are likely direct.
Stimulation of HepG2 cells by IL-1β leads to phosphorylation of Elk-1
Elk-1 is bound to the promoters of genes independently of its activation by the MAPK pathway [13, 9]. The crucial factor which changes the state of the Elk-1 on the promoters and induces events leading to activation of the genes regulated by this transcription factor is phosphorylation carried out by ERK, JNK or p38. To test whether active, phosphorylated forms of Elk-1 could be detected on the ZC3H12A promoter after IL-1β stimulation, we performed chromatin immunoprecipitation using anti-phospho-Elk-1 (P-Ser383) antibody. Phosphorylated Elk-1 could be detected on the ZC3H12A promoter after 15 min treatment with IL-1β (Fig. 4B).
Taken together, these results demonstrate that IL-1β treatment leads to the increase of Elk-1 phosphorylation in an ERK pathway-dependent manner and the active phosphorylated form can be found associated with the ZC3H12A promoter.
The ZC3H12A promoter is regulated by IL-1β via the ERK MAPK pathway
Functional analysis of ets binding site and CArG box in the ZC3H12A promoter
To confirm that the mutant promoter was unresponsive to Elk-1, we examined its activation by the potent Elk-VP16 fusion protein. In comparison to the wild-type promoter, the reporter construct containing the mutated ets binding site and the mutated CArG box was not responsive to Elk-VP16 (Fig. 6B). Mutation of either the Elk-1 or the SRF binding sites was sufficient to abolish activation of the promoter by Elk-VP16 (Fig. 6C). This is consistent with a requirement for SRF to recruit Elk-1.
Together these data therefore demonstrate the importance of the ets and SRF binding elements in promoter responsiveness to Elk-1 activity and activation by IL-1β.
Elk-1 is a known regulator of the expression of immediate-early genes, mainly transcription factors, which in turn regulate the expression of other genes coding for proteins engaged in the response of the cell to the changing environment. Thus, activation of Elk-1 is at the top of events leading to a global changes in the cell behavior. Here we have identified a new Elk-1 target gene, ZC3H12A, that encodes a recently discovered protein whose biological function is the control of mRNA turn-over. Transcripts for IL-6, IL-12p40 and the calcitonin receptor are found to be regulated by MCPIP  and we have recently found that MCPIP regulates the turn-over of IL-1β mRNA . The latter finding is intriguing and suggests the existence of an autoregulatory loop as here we show the importance of IL-1β in controlling the expression of ZC3H12A. The results indicate the existence of a negative regulatory loop, contributing to shut down of IL-1β synthesis.
The mechanisms controlling the regulation of the expression of ZC3H12A are not known. ZC3H12A is an immediate-early gene regulated by the proinflammatory cytokine IL-1β  through the activation of NFκB (Fig. 1; ). However in the mIκB cells with a defect in the activation of NFκB, IL-1β is still able to elevate MCPIP mRNA level (Fig. 1B). Our results suggest that apart from the NFκB activation pathway, the MAPK pathway is also engaged in the regulation of ZC3H12A expression. ZC3H12A promoter deletion constructs allowed us to find a minimal promoter 136 bp fragment which is still responsive to MAPK pathway activation. Bioinformatic analysis revealed that this region contains a hypothetical Elk-1 binding site (ets-binding site) - CAGGAA. The sequences recognized by Elk-1 differ amongst binding sites. The core GGA is always included in the ets-binding site but the flanking residues may differ. The most frequent motif is CCGGAA (in promoters of the Elk-1-regulated genes such as EGR-1, TR3, Pip92, MCL-1, SRF) [14, 15, 13]. However, other known Elk-1 target genes like c-FOS possess the sequence CAGGAT, whereas another one nur77, contains the GAGGAA motif [16, 14]. Elk-1 as a member of the TCF subfamily can form ternary complexes on target promoters together with serum response factor (SRF). Indeed, there is a CArG box, an SRF binding site, in the 136 bp fragment of ZC3H12A promoter (CCATATAAAGG). The consensus CArG box sequence is CC(A/T)6GG although there are exceptions from this rule. For example TR3 has CCTGTATGG and nur77 CTATTTATAG . The lack of one of the G:C base pairs flanking the central hexameric A/T rich region probably explains the lower level of binding we observe in comparison to the c-FOS promoter, which contains a canonical binding motif. However, the relative in vitro binding affinity and match to the consensus does not necessarily correlate with in vivo occupancy level as demonstrated by ChIP-chip analysis . Indeed, we detect SRF binding by ChIP analysis to this promoter. Simultaneous mutation of both, the ets-binding site and CArG box completely blocked activation of 136 bp promoter fragment by either a constitutively active form of Elk-1 (Elk-VP16) or by PMA treatment. Activation of this fragment by IL-1β is strongly reduced although not blocked completely and this remaining responsiveness to IL-1β is probably due to two hypothetical NFkB binding sites still present in the 136 bp promoter fragment [Skalniak unpublished]. All these results suggest involvement of the ERK MAPK pathway leading to activation of Elk-1 in the regulation of ZC3H12A expression by IL-1β. Indeed, we demonstrate binding of Elk-1 to ZC3H12A promoter in vivo through ChIP analysis. Elk-1 binding to the ZC3H12A promoter is detectable in the presence and absence of stimulation with IL-1β, thus, changes in promoter occupancy does not appear to be the activation mechanism. Binding of Elk-1 to ets-binding sites of other genes in unstimulated cells was reported earlier . Such binding is not sufficient for activation of genes regulated by Elk-1 since Elk-1 in unstimulated cells is sumoylated and interacts with HDAC-2. This modification keeps Elk-1 in a repressive form . Our data show that IL-1β induces phosphorylation of Elk-1 and phosphorylated Elk-1 is present on the ZC3H12A promoter (Fig. 4). The Elk-1 partner protein, SRF, is also bound to the ZC3H12A promoter and this binding is also not increased upon IL-1β stimulation indicating again that transcription factor recruitment does not appear to be a key regulatory event (Fig. 3C). This seems to be a more general mechanism since the occupancy of EGR-1 promoter by SRF and Elk-1 is also independent of IL-1β stimulation. It has to be noticed that apart from the NFκB activation pathway and the ERK pathway another yet unknown pathway contributes to the regulation of ZC3H12A expression. In mIκB cells treated with the ERK inhibitor the activation of ZC3H12A expression by IL-1β is still observed (Fig. 1). Our preliminary data indicate that p38 and JNK could participate in this process.
In summary, our results demonstrate a role of Elk-1 in the regulation of the expression of MCPIP - an RNAse important in inflammation. Until now, Elk-1 was generally thought to be involved in regulation of proliferation and apoptosis . Our discovery has therefore potentially broadened the role of Elk-1 as factor which also controls the course of inflammation.
HepG2 cells (ATCC), MOCK cells and mIκB cells were cultured at 37°C and 5%CO2 in Dulbecco Modified Eagle Medium (DMEM) with 1000 mg/l D-glucose (Gibco/BRL) supplemented with 10% foetal bovine serum (FBS). HepG2 cells stably transfected with retroviral vector pCFG5-IEG2, containing a nondegradable mutant form of IκBα (mIκB cells), and cells with an empty vector (control, MOCK cells) were used for determination of significance of NFκB signalling pathway in IL-1-dependednt activation of ZC3H12A. The transfected cells were kindly provided by Professor Stephan Ludwig (Heinrich-Heine University, Duesseldorf, Germany .
Human monocyte-derived macrophages (hMDMs) were separated from fractions of peripheral blood mononuclear cells (PBMCs) obtained from the blood of healthy donors using a lymphocyte separation medium (LSM; PAA) density gradient . Briefly, isolated PBMCs were seeded 2 × 107 /well in 6-well plates (Sarstedt) in RPMI1640 (PAA) containing 2 mM L-glutamine, 50 μg ml-1 gentamycin (Sigma), and 10% heat-inactivated autologous human plasma. After 24 h non-adherent cells were removed and remaining adherent monocytes were cultured for 7 days with fresh medium added every second day. The amount of serum was diminished to 0,5% 16 h before stimulation. hMDMs were stimulated with IL-1β (15ng/ml) for 2 h. When necessary an inhibitor U0126 was added 0,5 h before the cytokine stimulation.
Cytokine and cell stimulation
Cells were stimulated with 15 ng/ml IL-1β (R&D), 100 nM PMA (Calbiochem). When applied, the inhibitor of MEK1/2, U0126 (10 μM) (Calbiochem) was added to the medium at 30 min prior stimulation.
RNA preparation, Northern blot analysis and Real Time PCR
Total RNA was prepared using Chomczynski method with modifications as described before . Ten microgram samples of RNA were subjected to formaldehyde gel electrophoresis and northern blot analysis was carried out as described previously . For RT-PCR the first strand of cDNA was synthesized from 2 μg of total RNA using MMLV reverse transcriptase (Promega) and oligo(dT) primer. Real time PCR was performed using the SYBR Green PCR Master Mix (DyNAmo™ HS SYBR Green qPCR (Finnzyme). Each sample was normalized to reference gene (elongation factor 2) and the relative level of transcripts was quantified by ΔΔCT method.
Nuclear extract preparation and EMSA test
HepG2, MOCK cells and mIκB cells were stimulated with IL-1β for 90 min Nuclear extracts from stimulated and unstimulated cells were prepared as described previously . For NFκB binding assay double-stranded probes were labeled by filling in 5' protruding ends with Klenow enzyme using [α-32P]dCTP (3000 Ci/mmol). After purification with Qiagen system, the probes (10000-20000 cpm of 32P-labelled NFκB-binding oligonucleotide: 5'agcttcagaggggactttccgagagg) were incubated with 10 μg of nuclear extracts for 30 min at room temperature. For SRF binding gel retardation assay was carried out with 32P-labeled 162-base pair fragment of human ZC3H12A promoter generated by PCR on templates pS-ZC3H12A-luc (WT) and pS-ZC3H12A-luc (mCArG) (primers: GCCGCGACGCGAGGAGCGG and GTCCTGGGGGTAAGGACGGCG) as described previously . CoreSRF was produced as a glutathione S-transferase-tagged protein in bacteria.
pEF1/Myc-His/lacZ is a control vector containing the gene for β-galactosidase (Invitrogen). pElk-VP16 is a Rous sarcoma virus promoter-driven vector encoding full-length wild type Elk-1 fused to residue 410-490 of the VP16 C-terminal sequence [22, 13]. pElk-En is a CMV promoter-driven vector encoding full-length wild type Elk-1 fused to residue 2-298 of the engrailed repressor domain . pZC3H12A-luc, containing 2038 bp long fragment of human ZC3H12A promoter (-1050 - +988), was generated by PCR cloning of this fragment to the pGL4 reporter vector (Promega). The 2038 bp fragment of human ZC3H12A promoter was obtained by two step PCR, using total DNA isolated from HepG2 cells. The first round PCR was carried out with the primer forward: GTGGCTCTGTCCTCCAGCGTGT and reverse: CTGGCTTCCAGGACAGGCTTC. Then the second round of PCR was performed with nested primers: forward with restriction site for XhoI: CCGCTCGAGCTCCAGCGTGTGGGCTCTGTG and reverse with restriction site for HindIII and mutated initiation of translation codon ATG: CCCAAGCTTGCCACTGATAGCTCAGACTCCTG The introduced restriction sites were used during cloning of PCR product into the pGL4 vector. pS-ZC3H12A-luc, containing 136 bp long fragment of human ZC3H12A promoter (-76 - + 60) was generated using PCR product obtained with the following primers: forward with XhoI restriction site: CTCGAGAGCAGGAAGGGGCGAGGCAGCC and reverse with HindIII restriction site: GGGAAGCTTCGGCGGCGCCTTTATATGGGGCG and using pZC3H12A-luc as a template. All genetic constructs were sequenced before transfection experiments. The constructs containing mutations in ets-binding site or CArG box were generated using QuickChange Site-Directed Mutagenesis kit (Stratagene) according to the manufacturer's procedure. The sequence GCAGGAA was changed to GaAttcA, the sequence CCATATAAAGGC was changed to CCATATgaattc, both mutations generated EcoRI restriction site.
Reporter gene assay
Transient transfection experiments were carried out using Lipofectamine 2000 reagent (Invitrogen) in 12-weel plate. Total amount of 1.6 μg of DNA per each well was used, including 0.4 μg of pZC3H12A-luc or pS-ZC3H12A-luc and 10 ng of pEF1/Myc-His/lacZ. For some experiments indicated amounts of pElk-En or Elk-VP16 were used. The amount of DNA per well was equalized using mock DNA (pcDNA3). Luciferase assays were carried out using the dual light reporter gene assay system (Tropix) according to the manufacturer's procedure. β-galactosidase activity was measured to normalized the efficiency of transfection. All experiments were repeated at least three times in duplicates.
Western blot was carried out using Immobilon Western chemiluminescent HRP substrate (Millipore) and antibodies anti-phospho-Elk-1, anti-phospho-ERK (Santa Cruz) and anti-GAPDH (Abcam).
Chromatin immunoprecipitations were carried out as described previously , using anti-Elk-1, anti-P-Elk (P-Ser383) and anti-SRF (Santa Cruz) or nonspecific IgG (Upstate) antibodies. Promoter-specific primers were used to amplify the DNA by PCR: human ZC3H12A promoter: forward: CAGGTGCGTGTACCTGATTC and rewerse: CGAGTCCTGGGGGTAAGG, and human egr-1 promoter: forward: TGCAGGATGGAGGTGCC and reverse: AGTTCTGCGCGCTGGGATCTC. Where indicated cells were stimulated 30 min by IL-1β (15 ng/ml).
We thank Joanna Bereta for comments on the manuscript and stimulating discussions. The study was supported by the Polish Ministry of Scientific Research and Information Technology: 2P04A07829 (to AK) and 63/6PR-UE/2007/7 (to JJ), the Wellcome Trust (to ADS) and by the European Community's FP6: LSHM-CT-2006-036903 (to JJ).
- Matsushita K, Takeuchi O, Standley DM, Kumagai Y, Kawagoe T, Miyake T, Satoh T, Kato H, Tsujimura T, Nakamura H, Akira S: ZC3H12A is an RNase essential for controlling immune responses by regulating mRNA decay. Nature. 2009, 458: 1185-90. 10.1038/nature07924View ArticlePubMedGoogle Scholar
- Mizgalska D, Wκgrzyn P, Murzyn K, Kasza A, Koj A, Jura J, Jarząb J, Jura J: Interleukin-1-inducible MCPIP protein has structural and functional properties of RNase participating in degradation of IL-1-mRNA. FEBS J. 2009, 276: 7386-7399. 10.1111/j.1742-4658.2009.07452.xView ArticlePubMedGoogle Scholar
- Zhou L, Azfer A, Niu J, Graham S, Choudhury M, Adamski FM, Younce C, Binkley PF, Kolattukudy PE: Monocyte chemoattractant protein-1 induces a novel transcription factor that causes cardiac myocyte apoptosis and ventricular dysfunction. Circ Res. 2006, 98: 1177-85. 10.1161/01.RES.0000220106.64661.71View ArticlePubMedPubMed CentralGoogle Scholar
- Jiang Z, Ninomiya-Tsuji J, Qian Y, Matsumoto K, Li X: Interleukin-1 (IL-1) receptor-associated kinase-dependent IL-1-induced signaling complexes phosphorylate TAK1 and TAB2 at the plasma membrane and activate TAK1 in the cytosol. Mol Cell Biol. 2002, 22: 7158-67. 10.1128/MCB.22.20.7158-7167.2002View ArticlePubMedPubMed CentralGoogle Scholar
- Sharrocks AD: The ETS-domain transcription factor family. Nat Rev Mol Cell Biol. 2001, 2: 827-37. 10.1038/35099076View ArticlePubMedGoogle Scholar
- Yang SH, Jaffray E, Hay RT, Sharrocks AD: Dynamic interplay of the SUMO and ERK pathways in regulating Elk-1 transcriptional activity. Mol Cell. 2003, 12: 63-74. 10.1016/S1097-2765(03)00265-XView ArticlePubMedGoogle Scholar
- Stevens JL, Cantin GT, Wang G, Shevchenko A, Shevchenko A, Berk AJ: Transcription control by E1A and MAP kinase pathway via Sur2 mediator subunit. Science. 2002, 296: 755-8. 10.1126/science.1068943View ArticlePubMedGoogle Scholar
- Li QJ, Yang SH, Maeda Y, Sladek FM, Sharrocks AD, Martins-Green M: MAP kinase phosphorylation-dependent activation of Elk-1 leads to activation of the co-activator p300. EMBO J. 2003, 22: 281-91. 10.1093/emboj/cdg028View ArticlePubMedPubMed CentralGoogle Scholar
- O'Donnell A, Yang SH, Sharrocks AD: MAP kinase-mediated c-fos regulation relies on a histone acetylation relay switch. Mol Cell. 2008, 29: 780-5. 10.1016/j.molcel.2008.01.019View ArticlePubMedPubMed CentralGoogle Scholar
- Skalniak L, Zarebski A, Mizgalska D, Wyrzykowska P, Koj A, Jura J: NF-kappaB-dependent induction of the MCP-1 induced protein (MCPIP1) transcription upon IL-1 beta stimulation. FEBS J. 2009, 276: 5892-905. 10.1111/j.1742-4658.2009.07273.xView ArticlePubMedGoogle Scholar
- Yang SH, Whitmarsh AJ, Davis RJ, Sharrocks AD: Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J. 1998, 17: 1740-9. 10.1093/emboj/17.6.1740View ArticlePubMedPubMed CentralGoogle Scholar
- Mountain DJ, Singh M, Menon B, Singh K: Interleukin-1beta increases expression and activity of matrix metalloproteinase-2 in cardiac microvascular endothelial cells: role of PKCalpha/beta1 and MAPKs. Am J Physiol Cell Physiol. 2007, 292: C867-75. 10.1152/ajpcell.00161.2006View ArticlePubMedGoogle Scholar
- Kasza A, O'Donnell A, Gascoigne K, Zeef LA, Hayes A, Sharrocks AD: The ETS domain transcription factor Elk-1 regulates the expression of its partner protein, SRF. J Biol Chem. 2005, 280: 1149-55. 10.1074/jbc.M411161200View ArticlePubMedGoogle Scholar
- Latinkić BV, Zeremski M, Lau LF: Elk-1 can recruit SRF to form a ternary complex upon the serum response element. Nucleic Acids Res. 1996, 24: 1345-51. 10.1093/nar/24.7.1345View ArticlePubMedPubMed CentralGoogle Scholar
- Townsend KJ, Zhou P, Qian L, Bieszczad CK, Lowrey CH, Yen A, Craig RW: Regulation of MCL1 through a serum response factor/Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. J Biol Chem. 1999, 274: 1801-13. 10.1074/jbc.274.3.1801View ArticlePubMedGoogle Scholar
- Ling Y, Lakey JH, Roberts CE, Sharrocks AD: Molecular characterization of the B-box protein-protein interaction motif of the ETS-domain transcription factor Elk-1. EMBO J. 1997, 16: 2431-40. 10.1093/emboj/16.9.2431View ArticlePubMedPubMed CentralGoogle Scholar
- Boros J, Donaldson IJ, O'Donnell A, Odrowaz ZA, Zeef L, Lupien M, Meyer CA, Liu XS, Brown M, Sharrocks AD: Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery. Genome Res. 2009, 19: 1963-1973. 10.1101/gr.093047.109View ArticlePubMedPubMed CentralGoogle Scholar
- Vickers ER, Kasza A, Kurnaz IA, Seifert A, Zeef LA, O'donnell A, Hayes A, Sharrocks AD: Ternary complex factor-serum response factor complex-regulated gene activity is required for cellular proliferation and inhibition of apoptotic cell death. Mol Cell Biol. 2004, 24: 10340-51. 10.1128/MCB.24.23.10340-10351.2004View ArticlePubMedPubMed CentralGoogle Scholar
- Wurzer WJ, Ehrhardt C, Pleschka S, Berberich-Siebelt F, Wolff T, Walczak H, Planz O, Ludwig S: NF-kappaB-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas/FasL is crucial for efficient influenza virus propagation. J Biol Chem. 2004, 279: 30931-30937. 10.1074/jbc.M403258200View ArticlePubMedGoogle Scholar
- Kubica M, Guzik K, Koziel J, Zarebski M, Richter W, Gajkowska B, Golda A, Maciag-Gudowska A, Brix K, Shaw L, Foster T, Potempa J: A potential new pathway for Staphylococcus aureus dissemination: the silent survival of S. aureus phagocytosed by human monocyte-derived macrophages. PLoS ONE. 2008, 3: e1409- 10.1371/journal.pone.0001409View ArticlePubMedPubMed CentralGoogle Scholar
- Jura J, Wegrzyn P, Zarebski A, Władyka B, Koj A: Identification of changes in the transcriptome profile of human hepatoma HepG2 cells stimulated with interleukin-1 beta. Biochim Biophys Acta. 2004, 1689: 120-33.View ArticlePubMedGoogle Scholar
- Kasza A, Kiss DL, Goplan S, Xu W, Rydel RE, Koj A, Kordula T: Mechanism of plasminogen activator inhibitor-1 regulation by oncostatin M and interleukin-1 in human astrocytes. J Neurochem. 2002, 83: 696-703. 10.1046/j.1471-4159.2002.01163.xView ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.